炎症性肠病免疫调节剂与生物制剂降阶治疗的临床指南
本文综述了炎症性肠病中免疫调节剂和生物制剂降阶治疗的文献,指出降阶时疾病活动度、疾病预后特征和既往病程是复发风险因素,主要来自回顾性研究,可据此进行风险分层。综述提供了将降阶策略应用于临床实践的框架,并提及前瞻性试验正在进行中。
要点
- 降阶治疗需权衡继续用药风险与疾病复发风险。
- 降阶时疾病活动度、预后特征和既往病程可预测复发。
- 现有证据主要来自回顾性研究,需前瞻性试验进一步验证。
核心结论
- 降阶治疗决策应基于患者个体复发风险分层,现有证据多来自回顾性研究。
研究设计与样本
- 综述评估已发表的关于治疗降阶的文献,并提供临床实践框架。
主要发现
- 降阶时疾病活动度、疾病预后特征和既往病程是疾病复发的风险因素,主要来自回顾性研究。
临床怎么用
- 医生可依据已识别的风险因素对患者进行风险分层,应用于降阶治疗决策。
局限性
- 风险因素主要来自回顾性研究,前瞻性试验正在进行中,尚缺乏高级别证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
De-escalation of immunomodulators and biologic agents in inflammatory bowel disease is frequently discussed with patients and must weigh the risk of continued medical therapy with the risk of disease recurrence. Risk factors for disease flare after withdrawal of inflammatory bowel disease medications such as disease activity at de-escalation, disease prognostic features, and prior course of disease have been identified predominately in retrospective studies, allowing for risk stratification of patients. This review evaluates the published literature regarding therapeutic de-escalation and provides a framework for physicians to apply this to clinical practice. Prospective trials are underway and planned, which should provide further insight into this treatment paradigm and better inform patient selection for this strategy.
引用
- Hirten RP, Lakatos PL, Halfvarson J, et al. A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31887444. doi:10.1016/j.cgh.2019.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。